title: [Neoadjuvant hormonal treatment combined with external irradiation in the management of prostate cancer].
abstract: RTOG and EORTC trials have paved the way of the combination of radiation therapy and androgen suppression. Localized carcinoma with intermediate prognostic factors (cT2b, Gleason 7, or baseline PSA ranging between 10 and 20 ng/mL) may be submitted to a 4-month complete androgene blockade with 2 months before irradiation, unless to include patients in ongoing randomized trials. High risk cancers (cT2c, or Gleason > 7, or PSA > 20 ng/ml) should receive a 4-month or 6-month complete androgen blockade (RTOG trial 86-10), knowing that the results of EORTC trial 22961 are eagerly expected to tell us whether a 3- year androgen suppression is preferable. Very high risk prostate cancers, T3-4 N0 M0 or pelvic lymph node involvement (c or pN1) whatever the UICC T stage, need a long term androgen suppression of 3 years or more.
authors.affiliation: Département de cancérologie-hématologie, Service d'urologie, Centre hospitalier universitaire, BP 392, 63011 Grenoble. MBolla@chu-grenoble.fr
authors.forename: Michel
authors.initials: M
authors.lastname: Bolla
authors.forename: Xavier
authors.initials: X
authors.lastname: Artignan
authors.forename: Philippe
authors.initials: P
authors.lastname: Fourneret
authors.forename: Danielle
authors.initials: D
authors.lastname: Brochon
authors.forename: François
authors.initials: F
authors.lastname: Ringeisen
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Descotes
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy / Q000379:methods*; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal